Montelukast Voor Pediatrische Patiënten Van 2 Tot 5 Jaar Accord

Montelukast, the active ingredient in Montelukast Voor Pediatrische Patiënten Van 2 Tot 5 Jaar Accord, is a leukotriene receptor antagonist presented as an oral formulation for oral use. It is indicated for the management of asthma and allergic rhinitis in children aged two to five years.

GNH USA supplies Montelukast Voor Pediatrische Patiënten Van 2 Tot 5 Jaar Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and healthcare providers across multiple continents and regions.

Montelukast acts on leukotriene pathways to control chronic airway inflammation and allergic symptoms. It is clinically employed for the following indications: - Asthma: improves symptom control and reduces the frequency of exacerbations in children. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhoea. - Exercise‑induced bronchospasm: prevents bronchoconstriction triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache reported. - Abdominal pain: occasional stomach discomfort. - Cough: transient cough may appear. - Nausea: occasional feeling of nausea. - Sore throat: mild irritation of the throat. - Fever: low‑grade fever in some patients.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, agitation or suicidal thoughts. - Hepatic enzyme elevation: rare increase in liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Montelukast, consider the following safety measures: - Age limitation: use only in children 2–5 years as directed by a prescriber. - Renal or hepatic impairment: monitor liver and kidney function if disease is present. - Concomitant asthma therapy: continue inhaled corticosteroids or bronchodilators as needed. - Pregnancy: category B; discuss potential risks with the obstetrician. - Adherence: do not discontinue abruptly without medical advice. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Montelukast may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations. - Phenobarbital, carbamazepine, phenytoin: strong enzyme inducers that may reduce efficacy. - Strong CYP3A4 inducers: may lower therapeutic levels.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): monitor for neuropsychiatric effects. - Warfarin: observe INR values for potential alteration. - Short‑acting β2‑agonists: assess asthma control when used together.